At 6.9% CAGR, the South & Central America Structural Heart Market is Projected to be Worth US$ 1,148.35 million by 2028, says Business Market Insights

According to Business Market Insights research, the South & Central America structural heart market was valued at US$ 770.68 million in 2022 and is expected to reach US$ 1,148.35 million by 2028, registering a CAGR of 6.9% from 2022 to 2028. Availability of innovative structural heart services and rise in the number of cardiovascular diseases and training programs are the factors attributed to the South & Central America structural heart market expansion.

The availability of technologically advanced products and treatment services allows surgeons, physicians, and other healthcare providers to offer superior services to their patients, which helps them maintain the optimum quality of life. The innovations are not limited to healthcare facilities, and they are extended to programs that are being designed for patients to get benefits out of treatment facilities. Heart diseases are complex, and the success of their intervention depends on innovations bringing treatment options that were deemed impossible earlier into reality. The heart disease treatment landscape—from structural inventions to surgical valve therapies—has experienced breakthrough innovations over the past few decades. Companies in the South & Central America Structural heart market offer a broad portfolio of solutions for different heart conditions, including vascular disease, irregular heartbeats, and heart valve diseases. Physicians can now manage arrhythmias by using remote monitoring devices to keep a tab on their patients, thereby treating an array of structural heart conditions. The food and Drug Administration (FDA) have approved various therapies that are limited to the selected groups the patients. For instance, Premier Health, one of the providers of innovative structural heart services, offers alcohol septal ablation treatment for hypertrophic cardiomyopathy. The treatment mainly uses a catheter-based technology. The balloon valvuloplasty, uses a transcatheter approach for widening up stiff and narrow heart valves, atrial septal defect transcatheter repair which closes an opening between the heart’s left and right atrium without surgery and such more services are being provided by the service providers. CentraCare's Heart & Vascular Center used EchoPixel's True3D and HTG pre-planning software, which provides mixed reality capabilities that allow structural heart care teams to interact with a real-time holographic version of the patient's anatomy without physically touching it or exposing it to contrast agents and radiations. In August 2021, the first 3D-printed heart valve of an Indian make was developed in Chennai. The innovative technologies and techniques of structural heart programs are specifically designed to provide quality care for the best results for patients and provides less complications and shorter recovery times with long-lasting advantages. Such technologies are likely to attract more patients suffering from the structural heart diseases and eventually the benefits of the services are likely to enhance the growth of the market in the forecasted period.

On the contrary, high cost of procedures hampers the South & Central America structural heart market. 

Based on product, the South & Central America structural heart market is segmented into occluders, annuloplasty rings, heart valve balloons, and others. The occluders segment held 39.7% share of South & Central America structural heart market in 2022, amassing US$ 306.15 million. It is projected to garner US$ 462.71 million by 2028 to expand at 7.1% CAGR during 2022–2028. 

Based on procedure, the South & Central America structural heart market is segmented into heart valve stenosis, heart valve regurgitation, and left atrial appendage closure. The heart valve stenosis segment held 39.6% share of South & Central America structural heart market in 2022, amassing US$ 305.13 million. It is projected to garner US$ 469.05 million by 2028 to expand at 7.4% CAGR during 2022–2028.

Based on end user, the South & Central America structural heart market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals segment held 46.0% share of South & Central America structural heart market in 2022, amassing US$ 354.75 million. It is projected to garner US$ 541.66 million by 2028 to expand at 7.3% CAGR during 2022–2028.

Based on country, the South & Central America structural heart market has been categorized into the Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that the Brazil captured 61.4% share of South & Central America structural heart market in 2022. It was assessed at US$ 473.23 million in 2022 and is likely to hit US$ 708.72 million by 2028, exhibiting a CAGR of 7.0% during 2022–2028.   

Key players operating in the South & Central America structural heart market are Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, Artivion Inc, Edwards Lifesciences Corp, Braile Biomedica Industry, and Commerce and Representations Ltd, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com